Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 14, 2025, recommended Final Dividend of 12 per equity share i.e. 600 % of the Face Value of Rs. 2/ Each Fully Paid Up for the Financial Year Ended March 31, 2025
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin reported strong consolidated FY25 results with revenue from operations rising to ₹22,708 crore from ₹20,011 crore in FY24, a growth of about 13.5%. Consolidated profit after tax jumped nearly 71% to ₹3,306 crore from ₹1,936 crore in FY24, with basic EPS of ₹71.95 (vs ₹42.05). Standalone PAT also grew about 71% to ₹3,973 crore on revenue of ₹16,968 crore. The Board recommended a final dividend of ₹12 per share (600% on face value of ₹2), totaling ₹547.9 crore, subject to shareholder approval. Key one-off items include a ₹856 crore provision for ongoing disputes, Glumetza litigation settlement of ~₹75 crore, and impairment charges of ~₹121 crore (consolidated). The company also approved transfer of its OTC and API R&D businesses to wholly owned subsidiaries.
Strong double-digit revenue growth and ~71% PAT growth, combined with a healthy 600% dividend, signal robust operational performance and shareholder returns. The one-off provisions and impairments temper the underlying picture but core profitability remains materially improved.